相关实验视频

Updated: Jan 7, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

揭示双向分子通路:舒甘温丹如何治疗同时出现的抑郁症和动脉样硬化

Peiying Huang¹, Weihang Peng², Jiangsheng Lu³

¹Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, The Fifth Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, China; Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.

Journal of ethnopharmacology

|December 25, 2025

概括

舒甘温丹 (SGWDD) 通过抑制CASP1和MMP9.9来有效治疗抑郁症和动脉样硬化. 这种草药向"脂质和动脉样硬化途径"和"酸盐代谢途径",以缓解并发性疾病.

科学领域:

心血管药理学心血管药理学
神经科学是一个神经科学.
草药研究草药研究

背景情况:

动脉样硬化和抑郁症是并发性疾病,其机制不完全理解.
舒甘文丹 (SGWDD) 是一种传统的草药,已知对这两种疾病的疗效.

研究的目的:

为了阐明抑郁症和动脉样硬化之间的分子联系.
研究SGWDD在治疗这种并发症中的治疗机制.

主要方法:

利用慢性不可预测的轻度压力 (CUMS) 和高脂肪饮食 (HFD) 的动物模型,以及THP-1泡细胞模型.
通过使用行为测试,LC-MS/MS,血清学测试,qPCR和西方斑点检测,研究了CASP1-和MMP9-介导的途径.

主要成果:

HFD诱导了动脉样硬化标志物,而CUMS则影响了行为和改变了神经递质水平.
CASP1和MMP9被确定为重点调节剂,加剧了这两种情况.
通过抑制CASP1和MMP9表达,SGWDD改善了动脉样硬化和抑郁症.

结论:

抑郁症通过动脉样硬化机制加剧动脉样硬化.
脂质和动脉样硬化路径,
动脉样硬化增加了抑郁症的易感性,通过
三甲代谢途径.
SGWDD通过抑制CASP1和MMP9来证明治疗潜力,解决了这些疾病之间的双向联系.

关键词:

动脉样硬化是一种动脉样硬化.抑郁症抑郁症抑郁症脱脂血症是什么意思脱脂血症是什么意思舒甘使用了脱剂.托芬代谢的代谢方式

更多相关视频

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...